Biological models to predict drug response in clinical trials and in individuals
01 — Market Opportunity
Massive market with systemic inefficiencies
The pharmaceutical industry faces unprecedented challenges with high failure rates, escalating costs, and lengthy development timelines creating massive opportunities for innovation.
02 — Competitive Advantages
Unique biology-first approach
Our platform starts with the structure of the drug, modeling its mechanistic interactions with the human body, to deliver superior prediction accuracy.
Proven Performance
Our model achieved ~85% accuracy when predicting the outcomes of recent Phase II and Phase III trials, demonstrating state-of-the-art results with validated improvements over industry baselines.
Biology-First Approach
Unlike competitors who focus on commercial factors, we predict trial outcomes using predicted biological activity, physicochemical properties, and target-disease evidence.
Comprehensive, Curated Data Assets
Integration of millions of preclinical assay results, including proprietary data, with ~150,000 clinical trials
Generalizable, Scalable Tech
The model achieved high accuracy on first-in-class drugs, generalizing to novel molecules with limited information in the public domain.
03 — Investment Documents
Legal and regulatory filings
Access our latest SEC filings and regulatory documents for comprehensive investment due diligence.
Form C
Official SEC filing document providing detailed company information, business model, financial statements, and investment terms for our current funding round.
Form C-AR
Annual progress report providing updates on business developments, financial performance, use of funds, and significant corporate events since our last filing.
Important: These documents contain forward-looking statements and are intended for qualified investors only. Please review all risk factors and disclosures before making any investment decisions. Past performance does not guarantee future results.